Drug-induced Lupus Anticoagulants and Antiphospholipid Antibodies

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2011 Dec 14

PMID 22160568

Citations 22

Authors

Jeffrey S Dlott

Robert A S Roubey

Affiliations

Soon will be listed here.

Abstract

Lupus anticoagulants (LA) are immunoglobulins (IgG, IgM, and/or IgA) which interfere with one or more of phospholipid-dependent in vitro coagulation tests, eg, activated partial thromboplastin time (aPTT), kaolin clotting time (KCT), dilute Russell viper venom time (dRVVT), and dilute prothrombin time (dPT). LAs may be seen in a variety of clinical settings including the primary antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE), other autoimmune diseases, secondary to infections, malignancies, and in association with certain drugs. LAs associated with the antiphospholipid syndrome and other autoimmune disease recognize certain phospholipid-binding proteins (β(2)-glycoprotein I [β(2)GPI] or prothrombin). Many drugs have been implicated as possibly causing LAs, although the majority of such cases are limited to a select few. Drug-induced LAs are heterogeneous, differing in laboratory findings as well as related clinical complications. This paper reviews the English medical literature on drug-induced LA and potential mechanisms of induction.

Citing Articles

The Performance of 2023 American College of Rheumatology (ACR) / European Alliance of Associations for Rheumatology (EULAR) Antiphospholipid Syndrome Classification Criteria in a Real-World Rheumatology Department.

Usta A, Yayla M, Uslu E, Sezer S, Us E, Ates A Mediterr J Hematol Infect Dis. 2024; 16(1):e2024074.

PMID: 39534708 PMC: 11556423. DOI: 10.4084/MJHID.2024.074.

Lupus Anticoagulant Detection under the Magnifying Glass.

Molinari A, Martini T, Banov L, Ierardi A, Leotta M, Strangio A J Clin Med. 2023; 12(20).

PMID: 37892792 PMC: 10607820. DOI: 10.3390/jcm12206654.

Presumptive phenobarbital-induced systemic lupus erythematosus in a domestic dog.

Phillips E, Kornya M, Collier A, Barry M, Morrison K, Reggeti F J Vet Intern Med. 2023; 37(6):2482-2487.

PMID: 37737539 PMC: 10658473. DOI: 10.1111/jvim.16882.

Calprotectin: two sides of the same coin.

Carnazzo V, Redi S, Basile V, Natali P, Gulli F, Equitani F Rheumatology (Oxford). 2023; 63(1):26-33.

PMID: 37603715 PMC: 10765140. DOI: 10.1093/rheumatology/kead405.

Antiphospholipid syndrome with renal and splenic infarction after blunt trauma: A case report.

Lee N, Jeong E, Jang H, Park Y, Kang J, Kim J World J Clin Cases. 2022; 10(26):9404-9410.

PMID: 36159402 PMC: 9477667. DOI: 10.12998/wjcc.v10.i26.9404.

References

Becker J, Winkler B, Klingert S, Brocker E . Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer. 1994; 73(6):1621-4. DOI: 10.1002/1097-0142(19940315)73:6<1621::aid-cncr2820730613>3.0.co;2-e. View

Ferraccioli G, Mecchia F, Di Poi E, Fabris M . Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis. 2002; 61(4):358-61. PMC: 1754062. DOI: 10.1136/ard.61.4.358. View

Asherson R, Zulman J, Hughes G . Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies. Ann Rheum Dis. 1989; 48(3):232-5. PMC: 1003727. DOI: 10.1136/ard.48.3.232. View

Merkel P, Lo G, Holbrook J, Tibbs A, Allen N, Davis Jr J . Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005; 142(8):620-6. DOI: 10.7326/0003-4819-142-8-200505030-00011. View

Ramos-Casals M, Brito-Zeron P, Soto M, Cuadrado M, Khamashta M . Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008; 22(5):847-61. DOI: 10.1016/j.berh.2008.09.008. View

Ferraro-Peyret C, Coury F, Tebib J, Bienvenu J, Fabien N . Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004; 6(6):R535-43. PMC: 1064868. DOI: 10.1186/ar1440. View

Zarrabi M, Zucker S, Miller F, Derman R, Romano G, Hartnett J . Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med. 1979; 91(2):194-9. DOI: 10.7326/0003-4819-91-2-194. View

Boxer M, Ellman L, Carvalho A . The lupus anticoagulant. Arthritis Rheum. 1976; 19(6):1244-8. DOI: 10.1002/art.1780190603. View

McNeil H, Simpson R, Chesterman C, Krilis S . Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990; 87(11):4120-4. PMC: 54059. DOI: 10.1073/pnas.87.11.4120. View

10.

Alarcon-Segovia D . Drug-induced lupus syndromes. Mayo Clin Proc. 1969; 44(9):664-81. View

11.

Kameda H, Mimori T, Kaburaki J, Fujii T, Takahashi T, Akaishi M . Systemic sclerosis complicated by procainamide-induced lupus and antiphospholipid syndrome. Br J Rheumatol. 1998; 37(11):1236-9. DOI: 10.1093/rheumatology/37.11.1236. View

12.

Zengotita H, Holt R . Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect. J Clin Psychiatry. 1986; 47(1):35-7. View

13.

Edwards R, Rick M, Wakem C . Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus. Arch Intern Med. 1981; 141(12):1688-90. View

14.

Wetter D, Davis M . Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009; 84(11):979-84. PMC: 2770909. DOI: 10.4065/84.11.979. View

15.

Sanfelippo M, Drayna C . Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis. Am J Clin Pathol. 1982; 77(3):275-9. DOI: 10.1093/ajcp/77.3.275. View

16.

El-Mallakh R, Donaldson J, Kranzler H, Racy A . Phenothiazine-associated lupus anticoagulant and thrombotic disease. Psychosomatics. 1988; 29(1):109-13. DOI: 10.1016/S0033-3182(88)72430-5. View

17.

Schleider M, Nachman R, Jaffe E, Coleman M . A clinical study of the lupus anticoagulant. Blood. 1976; 48(4):499-509. View

18.

Matsukawa Y, Satoh M, Itoh T, Nishinarita S, Horie T, Abe K . Plasmapheresis for a schizophrenic patient with drug-induced lupus anti-coagulant. J Int Med Res. 1996; 24(1):147-50. DOI: 10.1177/030006059602400119. View

19.

BOWIE E, THOMPSON Jr J, PASCUZZI C, OWEN Jr C . THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS. J Lab Clin Med. 1963; 62:416-30. View

20.

Vereckei E, Krivan G, Reti M, Szodoray P, Poor G, Kiss E . Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis. Scand J Rheumatol. 2010; 39(2):175-7. DOI: 10.3109/03009740902832753. View